Willingness to vaccinate or get vaccinated with an intradermal seasonal influenza vaccine: A survey of general practitioners and the general public in france and germany

Advances in Therapy

Volumn 28, Issue 7, 2011, Pages 555-565

  Arnou, Robert ^a   Frank, Matthias ^b   Hagel, Thomas ^c   Prébet, Alice ^d  

^a ALTI Clinical Research Network   (France)

^b General Practice   (Germany)

^c GfK Group   (Germany)

^d SANOFI PASTEUR   (France)

Author keywords

INTANZA; Intradermal influenza vaccine; Microneedle injection system; Survey; Vaccination coverage rate; Willingness to vaccinate get vaccinated

Indexed keywords

INFLUENZA VACCINE; SEASONAL INFLUENZA VACCINE; UNCLASSIFIED DRUG;

ADULT; CONTROLLED STUDY; DISEASE SEVERITY; FRANCE; GENERAL PRACTITIONER; GERMANY; HEALTH SURVEY; HIGH RISK PATIENT; HUMAN; IMMUNOGENICITY; INFLUENZA VACCINATION; MAJOR CLINICAL STUDY; PUBLIC HEALTH; QUESTIONNAIRE; REVIEW; RISK FACTOR; SEASONAL INFLUENZA;

AGED; ATTITUDE OF HEALTH PERSONNEL; FRANCE; GENERAL PRACTITIONERS; GERMANY; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; INJECTIONS, INTRADERMAL; PATIENT ACCEPTANCE OF HEALTH CARE; VACCINATION;

EID: 82455162520     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-011-0035-z     Document Type: Review

References (19)

1. World Health Organization. Influenza vaccines.WHO Position Paper. Wkly Epidemiol Rec.2005;80: 279-287.
2. European Centre for Disease Prevention andControl (ECDC). Seasonal influenza andvaccination -the facts. Available at: Http://ecdc.europa.eu/en/ healthtopics/Documents/0712-seasonal-human-influenza-vaccination.pdf.Accessed March 21, 2011.
3. Thompson WW, Shay DK, Weintraub E, et al.Mortality associated with influenza and respiratorysyncytial virus in the United States. J Am MedAssoc. 2003;289: 179-186. (Pubitemid 36068705)
4. World Health Assembly. Fifty-sixth World HealthAssembly; Resolution WHA56.19. WHO, Geneva,2003. Available at: Http://www.evm-vaccines.org/pdfs/wha- resolution-ipd.pdf. Accessed May 4,2011.
5. European Union. Council recommendation of 22December 2009 on seasonal influenza vaccination(2009/1019/EU). Off J Eur Union. 2009;348: 71-72. Available at: Http://eurlex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2009:348:0071: 0072:EN:PDF. Accessed March 21, 2011.
6. Samson SI, Mégard Y. Overview of vaccinationpolicies for the elderly in Western Europeancountries. Aging Clin Exp Res. 2009;21: 210-215.
7. Mereckiene J, Cotter S, D'Ancona F et al. VENICEproject gatekeepers group. Differences in nationalinfluenza vaccination policies across the EuropeanUnion, Norway and Iceland 2008-2009. EuroSurveill. 2010;15: Pii: 19700.
8. Arnou R, Eavis P, Pardo JR, Ambrozaitis A, KazekMP, Weber F. Immunogenicity, large scale safetyand lot consistency of an intradermal influenzavaccine in adults aged 18-60 years: Randomized,controlled, phase III trial. Hum Vaccin. 2010;6: 346-354.
9. Arnou R, Icardi G, De Decker M, et al. Intradermalinfluenza vaccine for older adults: A randomizedcontrolled multicenter phase III study. Vaccine.2009;27: 7304-7312.
10. Lambert PH, Laurent PE. Intradermal vaccinedelivery: Will new delivery systems transformvaccine administration? Vaccine. 2008;26: 3197-3208.
11. Nicolas JF, Guy B. Intradermal, epidermal andtranscutaneous vaccination: From immunology toclinical practice. Expert Rev Vaccines. 2008;7: 1201-1214.
12. Atmar RL, Patel SM, Keitel WA. Intanza®: A newintradermal vaccine for seasonal influenza. ExpertRev Vaccines. 2010;9: 1399-1409.
13. Nichol KL. The efficacy, effectiveness and cost-effectiveness of inactivated influenza virusvaccines. Vaccine. 2003;21: 1769-1775. (Pubitemid 36398371)
14. INTANZA® 9 and 15 (influenza vaccine injection)product information. France: Sanofi pasteur;2009. Available at: Http://www.ema.europa.eu/docs/en-GB/ document-library/EPAR-Product-Information/human/000957/WC500033852.pdf.Accessed March 21, 2011.
15. Reygrobellet C, Viala-Danten M, Meunier J,Weber F, Nguyen VH. Perception and acceptanceof intradermal vaccination: Patient-reportedoutcomes from phase 3 clinical trials. Hum Vaccin.2010;6: 336-345.
16. Johnson DR, Nichol KL, Lipczynski K. Barriers toadult immunization. Am J Med. 2008;121: S28-S35.
17. Blank PR, Schwenkglenks M, Szucs TD. Disparitiesin influenza vaccination coverage rates by targetgroup in five European countries: Trends over sevenconsecutive seasons. Infection. 2009;37: 390-400.
18. Blank PR, Schwenkglenks M, Szucs TD. Influenzavaccination coverage rates in five Europeancountries during season 2006/07 and trends oversix consecutive seasons. BMC Public Health.2008;8: 272.
19. Aballéa S, Chancellor J, Martin M, et al. The costeffectivenessof influenza vaccination for peopleaged 50 to 64 years: An international model. ValueHealth. 2007;10: 98-116. (Pubitemid 46481137)